

Integrative Strategies in Breast Cancer: Synergizing Modern Oncology and Ayurveda

Krishna Gopinath K¹, Dr. K. Elango²

¹Research Scholar, Department of Pharmacy Practice, Karpagam Academy of Higher Education, Coimbatore, India

²Professor, Department of Pharmacology, Karpagam Academy of Higher Education, Coimbatore, India

Abstract

Background: Breast cancer is still the most common cancer in women worldwide, and as its incidence and survival rate rise, more thorough, patient-centered care models are needed. Even though contemporary oncology provides evidence-based procedures, tailored medicines, and sophisticated diagnostic tools, it frequently fails to address long-term quality of life, immunological resilience, and overall well-being. Although India's traditional medical system, Ayurveda, offers centuries-old methods for systemic healing, little is known about how it might be integrated with oncology.

Objective: This review is to assess the therapeutic potential of an integrated approach to breast cancer therapy that blends Ayurvedic and contemporary oncology principles. Additionally, it intends to provide a path for safe, evidence-based clinical practice.

Methods: The Cochrane Library, AYUSH Research Portal, PubMed, and Scopus databases were used to do a literature evaluation. Research on Ayurvedic and conventional cancer treatment was reviewed, including studies on clinical models, pharmacovigilance, diagnostics, and therapies. Important Ayurvedic ideas were mapped against biological frameworks, including Prakriti-based therapies, Panchakarma, and Rasayana.

Results: Despite advancements in molecular profiling, immunotherapy, and tailored medication, survivors continue to experience problems such immunological malfunction, exhaustion, and psychological discomfort. When applied carefully, ayurvedic treatments have shown promise in boosting immune function, decreasing inflammation, increasing chemotherapy tolerance, and improving quality of life. Pilot studies, institutional programs, and case studies all point to the early advantages of integrative approaches. Standardization, research on herb-drug interactions, regulatory procedures, and interdisciplinary communication still face difficulties, nonetheless.

Conclusion: A potential paradigm for all-encompassing breast cancer care is provided by a synergistic model that combines the accuracy of modern oncology with the holistic basis of Ayurveda. To create a long-lasting framework for integrative oncology, future studies must concentrate on clinical validation, safety monitoring, systems biology techniques, and policy-level integration.

Keywords: Ayurveda, Rasayana, Chemotherapy, Herb-drug interactions, Personalized treatment, Panchakarma, Breast cancer, Integrative oncology, and Holistic care

1. INTRODUCTION

Breast cancer, which accounts for more than 2.3 million new cases each year worldwide, is still the most common malignancy among women and a major cause of cancer-related death [1]. Early detection, surgical methods, radiotherapy, chemotherapy, hormone therapy, and targeted biologics have all advanced significantly in modern oncology; however, recurrence, treatment resistance, and negative effects on patient's quality of life remain problems [2,3]. Despite their effectiveness, traditional treatments can come with heavy financial, emotional, and physical costs [4].

Integrative oncology, which integrates evidence-based conventional medicines with alternative techniques to maximize health, reduce symptoms, and improve treatment results, is becoming increasingly valued in response to these issues [5]. In this context, a possible supplementary approach is provided by Ayurveda, an ancient Indian medical system that emphasizes harmonizing body systems through nutrition, herbal remedies, lifestyle changes, and mind-body activities [6]. Individualized care, the idea of "Prakriti" (body constitution), detoxification (Panchakarma), and the application of natural pharmaceutical compounds with anti-inflammatory, antioxidant, immunomodulatory, and perhaps anticancer qualities are all emphasized in Ayurvedic principles [7,8]. Aswagandha (*Withania somnifera*), gunduchi (*Tinospora cordifolia*), and turmeric (*Curcuma longa*) are a few Ayurvedic formulations that have shown encouraging effects in reducing chemotherapy-induced toxicities, reducing weariness, and enhancing immune function [9,10]

Patients with breast cancer may benefit from an integrative approach that combines Ayurveda with contemporary oncology to promote overall health, decrease side effects, and increase therapeutic results. This review identifies future paths for research and practice while examining the clinical data, scientific justification, and implementation techniques for such an integrative strategy.

2. Impact of Modern Oncology in the Treatment of Cancer

Breast cancer is still one of the most common cancers in the world, and advances in oncology have significantly improved patient survival, treatment, and prognosis. The treatment of breast cancer has changed from a uniform approach to a more accurate, stratified model based on tumor biology and patient characteristics through advancements in early identification, molecular diagnostics, and customized therapy.

2.1 Advances in Diagnosis and Molecular Profiling

Developments in Molecular Profiling and Diagnosis Early-stage detection has significantly increased as a result of modern oncology's emphasis on early and precise diagnosis employing mammography, ultrasound, MRI, and image-guided biopsies [11,12]. Moreover, oncologists can now classify tumors into different biological types like luminal A, luminal B, HER2- enriched, and triple- negative breast cancer (TNBC), each of which requires a different treatment strategy, due to the molecular subtyping of breast cancer, which is based on the expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [13,14]. Oncotype DX and MammaPrint are two genomic diagnostics that have further influenced adjuvant chemotherapy choices, minimizing overtreatment and allowing for more individualized care [15].

2.2 Therapeutic Innovations and Survival Impact

Endocrine therapy, targeted biological treatments, radiation, and chemotherapy are the mainstays of contemporary treatment. Recurrence can still be decreased using regimens based on cyclophosphamide, anthracyclins, and taxanes [16]. For individuals with HER2, the advent of HER2- targeted treatments such as trastuzumab and pertuzumab has significantly improved results [17]. Similarly, hormone receptor-positive metastatic breast cancer now has more alternatives because of P13K inhibitors and CDK4/6 inhibitors (palbociclib, ribociclib) [18].

Still in its infancy, immunotherapy has showed promise, especially in triple-negative breast cancer, with drugs such as immune checkpoint inhibitor atezolizumab [19].

The 5-year survival rate has increased as a result of these developments. Even patients with metastatic breast cancer now have a much longer median survival, and the relative survival rate for localized breast cancer has risen to over 90% in affluent countries [20].

2.3 Minimally Invasive and Organ- Preserving Approaches

Breast- conserving surgery (BCS) with sentinel lymph node biopsy has become the preferred surgical technique, reducing the necessity for radical mastectomy while preserving oncological safety [21]. Patients now have better cosmetic results and a higher quality of life as a result of the development of surgical oncology and developments in reconstructive procedures [22]. Similarly, radiotherapy has become hypofractionated and more focused, which lowers the burden of treatment and collateral tissue damage [23].

2.4 Quality of Life and Survivorship

In order to treat long-term consequences such as cardiotoxicity, lymphedema, cognitive impairments, and psychological stress, modern oncology is increasingly incorporating survivorship care [24]. Emerging integrative models emphasize patient- centered care by integrating mental and physical health strategies.

3. Involvement of the Ayurvedic System in Breast Cancer

The Indian traditional medical system known as Ayurveda provides a comprehensive foundation for comprehending health and illness. Ayurveda offers a supplementary paradigm in the treatment of breast cancer that incorporates dietary, lifestyle, psychological, and physical aspects into treatment plans. Ayurvedic principles and practices are becoming more widely acknowledged for their beneficial function

in enhancing the quality of life, lowering side effects associated with therapy, and possibly modifying the course of the disease, even though they do not replace traditional oncological interventions.

3.1 Ayurvedic Understanding of Breast Cancer (Stana Arbuda)

Breast cancer is referred to in Ayurvedic literature as “Stana Arbuda” (stana = breast; arbuda = tumor), which is usually caused by aggravated tridoshas (pitta, kapha, and vata), especially vitiated vata and kapha doshas, which result in tissue overgrowth and blockage of body channels (srotas) [25,26]. Ayurvedic pathophysiology also links cancer to the buildup of ama (toxins) and the disturbance of agni (digestive/metabolic fire) [27].

3.2 Role of Herbal Therapies and Rasayana

Ayurveda uses a range of plant-based formulations and individual herbs because of their possible antioxidant, immunomodulatory, and anticancer effects. In preclinical trials, herbs including ashwagandha (*Withania somnifera*), guduchi (*Tinospora cordifolia*), turmeric (*Curcuma longa*), and neem (*Azadirachta indica*) have shown chemopreventive and anti-proliferative activities [28-30]. Ayurveda's Rasayana (rejuvenation) school places a strong emphasis on long-term systemic and immunological resilience. Shatavari (*Asparagus racemosus*) and Amalaki (*Embllica officinalis*) are two rasayana herbs that have long been utilized to promote vitality, re-establish homeostasis, and fight oxidative stress [31].

3.3 Panchakarma and Detoxification Approaches

Panchakarma, a five-pronged detoxification therapy, is used in Ayurveda to get rid of accumulated toxins and bring the doshic equilibrium back. Panchakarma treatments like Abhyanga (oil massage), Basti (medicated enemas), and Virechana (therapeutic purgation) are thought to boost immunity, decrease inflammation, and enhance systemic circulation in cancer patients receiving traditional treatments, even though they are not direct cancer therapies [32].

3.4 Integration in Supportive and Palliative Care

Chemotherapy and radiation side effects, including tiredness, mucositis, gastrointestinal distress, and neuropathy, have responded well to ayurvedic treatments. The immune system, psychological health, and digestive health are supported by the use of herbal decoctions, oils, and customized diets [33,34]. It is common practice to improve mental clarity and gastrointestinal health by using Ayurvedic formulations such as Brahmi ghrita, Draksharishta, and Triphala. Yoga and meditation are two Ayurvedic mind-body techniques that help survivors of breast cancer deal with the emotional and psychological aspects of the disease, lowering their levels of anxiety, despair, and insomnia [35]

3.5 Limitations and the Need for Evidence-Based Integration

There are obstacles to the therapeutic use of Ayurveda in the treatment of breast cancer, despite its extensive pharmacopoeia and systemic insights. These include difficulties in combining conventional diagnostics with biological oncology, standardization of formulations, and a dearth of extensive, randomized controlled trials [36]. Nonetheless, new evidence suggests that there is increasing interest in integrating Ayurvedic practices with traditional treatment under scientific examination, particularly from integrative oncology clinics in India and the West [37].

4. Integrative Oncology: Bridging the Two Systems

Integrative oncology is an evidence-based, patient-centered approach that addresses the physical, emotional, and spiritual aspects of recovery by combining alternative therapies with traditional cancer treatments. The combination of contemporary scientific therapies and ayurvedic principles in the treatment of breast cancer represents a growing movement in healthcare toward more individualized and holistic approaches. This convergence strives for synergy- improving overall quality of life, reducing toxicity, and increasing efficacy- rather than just additive effects.

4.1 Clinical Evidence for Integrative Care in Breast Cancer

Integrative oncology frameworks are being investigated by a number of Indian and International institutes. For example, pilot trials combining Ayurvedic formulations and practices with chemotherapy and radiation have been carried out by Banaras Hindu University (BHU), AIIMS Delhi, and the Tata

Memorial Centre [38]. According to these research, patient's appetite and emotional health can be enhanced by integrated treatment, which can also lessen the nausea, exhaustion, and mucositis brought on by chemotherapy. Integrative oncology clinics that provide yoga therapy, acupuncture, herbal consultations, and mind-body therapies for patients with breast cancer have been adopted by institutions such as Memorial Sloan Kettering and MD Anderson Cancer Centre in the West. Such programs have been shown to minimize tension and anxiety during active treatment, enhance symptom control, and increase patient satisfaction [39,40]. Rasayana support improved treatment adherence, reduced hematological toxicity, and increased energy levels in chemotherapy patients, according to an observational study done at the Cochrane Ayurveda Research Centre [41].

4.2 Case Reports and Pilot Studies

The benefits of Ayurvedic support for breast cancer survivors have been established in a number of case series. A 48 year-old patient with breast cancer receiving adjuvant chemotherapy reported better digestion, less fatigue, and psychological resilience after receiving customized Ayurvedic herbal support and yoga-based lifestyle counseling, according to 2021 case report published in the *Journal of Ayurveda and Integrative Medicine* [33]. Triphala, Ashwagandha, and Drakshavaleha have shown potential in reducing stress, sleep problems, and oral mucositis brought on by chemotherapy, according to pilot studies [42,43]. Similarly in multiple randomized controlled trials, Yoga Nidra and pranayama have shown quantifiable benefits in anxiety and depression levels among breast cancer survivors [35].

4.3 Safety, Standardization, and Herb-Drug Interactions

The possibility of herb-drug interactions is one of the main issues in integrative care, especially when using Ayurvedic herbs in combination with chemotherapy drugs. Herbs such as ashwagandha, tulsi, and turmeric may have an impact on drug metabolism or cytochrome P450 pathways [44]. Therefore, to guarantee safety and therapeutic coherence, coordinated treatment including both oncologists and Ayurvedic specialists is essential. Although further pharmacokinetic and toxicity profiling studies are needed for widespread acceptability, efforts are underway to standardize Ayurvedic medications through guidelines from the Ministry of AYUSH, ICMR, and CCRA YUSH [45]. Standard operating procedures (SOPs), shared patient information, and clinical documentation are also required for the management of integrative regimens. Public-private collaborations and initiatives like the National AYUSH Mission (NAM) could aid in formalizing this kind of interdisciplinary cooperation.

In brief Aligning philosophies—precision medicine with personalization, tumor-focused methods with systemic support, and curative intent with restorative care—is just as important as combining treatments to bridge the gap between modern oncology and Ayurveda. Thus, a collaborative, multidisciplinary framework that is evidence-based, patient-specific, and culturally sensitive is necessary in the developing field of integrative oncology in breast cancer.

5. Future Directions and Research Priorities

Though its implementation depends on well-defined scientific, regulatory, and clinical approaches, the merger of Ayurveda and modern oncology in breast cancer care holds tremendous potential. Future studies must prioritize interdisciplinary cooperation, patient-centered clinical models, and strong evidence creation as integrative oncology develops as a specialty. Below are key areas that warrant attention:

5.1 Integrative Protocols Clinical Trials

High-quality randomized controlled trials (RCTs) are required to confirm the efficacy, safety, and repeatability of Ayurvedic therapies as adjuncts in cancer care, even if preliminary studies and anecdotal data support this role. These tests ought to investigate:

- Rasayana therapy's contribution to improving chemotherapy tolerance and recuperation [46,33]
- Panchakarma techniques' effectiveness in lowering systemic inflammation and exhaustion [41]
- Ayurvedic lifestyle therapies (diet, sleep, meditation) and their long-term effects on survivability and recurrence.

Priority should be given to multicentric clinical studies, ideally conducted in association with organizations such as ICMR, Tata Memorial Centre, MD Anderson, and AYUSH Research Councils [47,48].

5.2 Mechanistic Studies and Systems Biology

Systems biology techniques are crucial for bridging the gap between Ayurvedic and biomedical perspectives. These consist of:

- Connecting Ayurvedic ideas (such doshas, agni, and ama) to metabolic and immunological indicators [49]
- Investigating herbal formulations and Rasayana medications using omics technologies (genomics, proteomics, and metabolomics)
- Assessing the cytoprotective, anti-inflammatory, and immune-modulatory properties of traditional Ayurvedic herbs.

Such information will improve the integration of Ayurvedic treatments with oncology and support their biological validity.

5.3 Pharmacovigilance and Standardization

The absence of standardized Ayurvedic formulations, dosing guidelines, and quality control is one of the main obstacles to integration. Future studies should concentrate on:

- Creating herbal products that adhere to Good Manufacturing Practices(GMP) [50]
- Determining the pharmacokinetic and pharmacodynamic characteristics of polyherbal medications.
- Establishing a system for pharmacovigilance to track adverse events and herb-drug interactions [51,52].

This procedure can be facilitated by regulatory partnerships between the Ministry of AYUSH, DCGI, and foreign health agencies.

5.4 Tools for Decision Support and Digital Health

As AI-powered clinical decision support systems and digital treatments proliferate, Ayurveda can be included into digital health platforms that:

- Align patients' constitutional type (prakriti) with suitable nutritional, lifestyle, and supportive measures.
- Utilize mobile health (mHealth) technologies to monitor patient outcomes during integrative treatment.
- Encourage oncologists and ayurvedic doctors to collaborate on decisions.

One possible approach is the creation of AI-powered algorithms that can provide safe and customized integrative regimens [53].

5.5 Models of Clinical and Educational Integration

Future initiatives should also prioritize:

- Establishing multidisciplinary integrative cancer training programs for physicians, Ayurvedic practitioners, nurses, and researchers [54]
- Establishing integrative cancer clinics in tertiary care facilities where Ayurvedic specialists and oncologists co-manage patient care
- Encouraging clinical electives and interdisciplinary research fellowships

These programs could be modeled at institutions like world cancer centers, BHU, NIMHANS, and AIIMS.

5.6 International Cooperation and Policy Assistance

International collaboration is necessary to guarantee the mainstreaming of integrative oncology. This comprises:

- Involvement in global collaborations such as Cochrane Complementary Medicine and the Society for Integrative Oncology Cooperative research initiatives in oncology and traditional medicine between the US, EU, and India [48].

- Creation of government funding programs and policies for integrative cancer research, such as through collaborative task forces between AYUSH and ICMR [55].

In brief Ayurvedic knowledge, cutting-edge technology, and rigorous clinical science must all be combined in the future of integrative breast cancer therapy. A smooth, evidence-based paradigm that improves therapy results while respecting patient choice, safety, and cultural identity should be the aim, going beyond parallel practice. We can establish a sustainable integrative oncology ecosystem that can act as a global paradigm by funding translational research, digital tools, and regulatory harmonization.

6. Challenges and Limitations

Obstacles and Restrictions The combination of contemporary cancer treatment with Ayurveda is still complicated, with a number of issues that need to be resolved to guarantee patient safety, scientific validity, and clinical acceptance, even with the growing interest in integrative oncology. These difficulties are seen in the fields of regulation, medicine, education, and epistemology.

6.1 Insufficiently Good Clinical Evidence

Robust randomized controlled trials (RCTs) are rare, despite the fact that numerous Ayurvedic therapies have demonstrated promise in preclinical research or pilot trials. The majority of research lacks long-term follow-up, control groups, a sufficient sample size, and a rigorous methodology [33,48]. Additionally, variations in patient profiles and formulations make it more difficult to reproduce and generalize results. To determine the actual effectiveness of Ayurvedic treatments of cancer, high-quality trials that satisfy contemporary scientific standards are desperately needed [46].

6.2 Ayurvedic Medicine Standardization and Quality Assurance

Multiple herbs are frequently used in Ayurvedic medicines, which makes standardization and uniformity extremely difficult. Inconsistent therapeutic results and safety issues may arise from differences in the source of raw materials, preparation techniques, and the absence of phytochemical profiling [56]. Oncologists' confidence is further undermined by the lack of Good Manufacturing Practices (GMP) in certain commercial medicines and lax regulatory enforcement [47].

6.3 Safety Issues and Herb-Drug Interactions

Numerous Ayurvedic herbs have the ability to alter enzymes like P-glycoprotein and cytochrome P450, which may conflict with chemotherapy drugs [52]. Sadly, there are presently few thorough pharmacokinetic and interaction studies available.

This presents a problem for doctors, who could be reluctant to permit the concurrent use of Western and Ayurvedic medications because of worries about toxicity or diminished effectiveness [44].

6.4 Disparities in Epistemology and Communication

Ayurvedic conceptual paradigms like doshas, agni, ama, and prakriti are difficult to reconcile with evidence-based frameworks and molecular biology. This makes it challenging to publish in reputable journals, interact with oncologists, and develop interdisciplinary methods [57].

Furthermore, professional silos and little collaborative practice result from the lack of integrative education in both Ayurvedic and allopathic curriculum [54].

6.5 Ethical and Regulatory Barriers

For integrative cancer care, there are no widely recognized standard operating procedures (SOPs) or clinical practice recommendations. Informed consent is another ethical issue that comes up when traditional therapies are introduced without enough proof, particularly in vulnerable groups like cancer patients [41].

Additionally, the speed of translational research is slowed by institutional resistance and a lack of financing for integrative investigations [58].

6.6 Limited Models of Global Integration and Acceptance

Although integrative oncology is becoming more popular in China, India, and some Western institutions, Ayurveda's use in oncology is still not widely accepted worldwide. Ayurvedic medicine is

not officially recognized in the majority of nations, and integrative models are frequently limited to supplementary or alternative care rather than cancer units [59].

In brief Multi-sectoral initiatives are needed to address these shortcomings, which include open communication between medical systems, interdisciplinary education, clearer regulatory frameworks, and strong scientific validation of Ayurvedic treatments. Only then can integrative oncology develop into a model for treating complicated diseases like breast cancer that is safe, reliable, and supported by data.

Futhermore, cross-border clinical partnerships and acceptability in multicentre trials are hampered by the absence of international agreement on Ayurvedic education requirements and clinical practice guidelines. Standardized training programs, regulatory frameworks, and collaborative infrastructure are necessary to facilitate the safe and evidence-based use of traditional systems like Ayurveda in cancer care globally, according to a global multicentre study of oncology and CAM professionals [60].

7. CONCLUSION

Breast cancer management has witnessed transformative progress through advances in modern oncology, including early detection, molecular subtyping, targeted therapies, and survivorship care. However, this precision-focused approach often overlooks the complex psycho-immune and lifestyle dimensions that influence long-term healing and quality of life. Ayurveda, with its centuries-old emphasis on systemic balance, individual constitution (prakriti), detoxification (shodhana), and rejuvenation (rasayana), offers a complementary perspective that addresses these unmet needs.

This review highlights that a thoughtfully designed integrative strategy – combining the strengths of both systems – can enhance therapeutic outcomes, minimize adverse effects, and improve patient satisfaction. Modern interventions like chemotherapy and immunotherapy can be supported by Ayurvedic adjuncts such as Ashwagandha, Triphala, and Panchakarma, which may reduce fatigue, inflammation, and immune suppression. Emerging evidence from clinical pilots and case studies suggests that integrative models improve chemotherapy adherence, reduce side effects, and support psychological resilience.

Nonetheless, the journey toward full integration is constrained by several challenges: insufficient high-quality clinical trials, limited standardization of Ayurvedic medicines, risk of herb-drug interactions, regulatory gaps, and epistemological differences between the two systems. Overcoming these hurdles demands multidisciplinary collaboration, cross-training between Ayurveda and oncology professionals, rigorous pharmacological studies, and policy-driven institutional frameworks.

Looking ahead, the future of integrative breast cancer care lies in developing personalized, evidence-based, and culturally contextual protocols that blend modern biomedical precision with Ayurvedic holistic wisdom. Such synergy holds the promise of a new era in oncology—one that not only targets the tumor but also nurtures the person.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209-249.
2. Waks AG, Winer EP. Breast cancer treatment: a review. *JAMA.* 2019;321(3):288-300.
3. Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. *Nat Rev Dis Primers.* 2019;5(1):66.
4. Chatterjee S, Gupta D, Capurso SA, et al. Health-related quality of life in breast cancer patients: a study from a tertiary cancer center in India. *Indian J Palliat Care.* 2021;27(1):117-122.
5. Witt CM, Balneaves LG, Cardoso MJ, et al. A comprehensive definition for integrative oncology. *J Natl Cancer Inst Monogr.* 2017;2017(52).
6. Patwardhan B, Chavan-Gautam P, Gautam M, et al. Ayurveda rasayana in cancer management: an evidence-based review. *J Integr Cancer Ther.* 2010;9(2):114-122.
7. Sharma H, Chandola HM, Singh G, Basisht G. Utilization of Ayurveda in health care: an approach for prevention, health promotion, and treatment of disease. Part 2—Ayurveda in primary health care. *J Altern Complement Med.* 2007;13(10):1135-1150.
8. Balasubramani SP, Venkatasubramanian P, Patwardhan B. Ayurveda insights on cancer biology. *J Altern Complement Med.* 2011;17(6):489-494.
9. Ghosh S, Banerjee S, Sil PC. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. *Food Chem Toxicol.* 2015;83:111-124.
10. Singh N, Bhalla M, de Jager P, Gilca M. An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda. *Afr J Tradit Complement Altern Med.* 2011;8(5 Suppl):208-213.
11. Tabár L, Vitak B, Chen THH, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. *Radiology.* 2011;260(3):658-663.

12. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update. *JAMA*. 2015;314(15):1599-1614.
13. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. *Nature*. 2000;406(6797):747-752.
14. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. *N Engl J Med*. 2009;360(8):790-800.
15. Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. *N Engl J Med*. 2016;375(8):717-729.
16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. *Lancet*. 2005;365(9472):1687-1717.
17. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*. 2001;344(11):783-792.
18. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N Engl J Med*. 2016;375(18):1738-1748.
19. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*. 2018;379(22):2108-2121.
20. DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(6):438-451.
21. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy. *N Engl J Med*. 2002;347(16):1227-1232.
22. Cordeiro PG. Breast reconstruction after surgery for breast cancer. *N Engl J Med*. 2008;359(15):1590-1601.
23. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. *N Engl J Med*. 2010;362(6):513-520.
24. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. *J Clin Oncol*. 2016;34(6):611-635.
25. Sharma PV. Charaka Samhita. Varanasi: Chaukhambha Orientalia; 2005.
26. Dash B, Sharma RK. Caraka Samhita: Text with English Translation & Critical Exposition Based on Cakrapani Datta's Ayurveda Dipika. Varanasi: Chowkhamba Sanskrit Series Office; 2001.
27. Dwivedi A, Dwivedi S. Ayurveda: The Science of Life, Health and Longevity. *Ayu*. 2007;28(1):18-24.
28. Davis L, Kuttan G. Effect of *Withania somnifera* on cytokine production in normal and tumor-bearing mice. *J Exp Clin Cancer Res*. 1999;18(2):195-199.
29. Jagetia GC, Aggarwal BB. "Spicing up" of the immune system by curcumin. *J Clin Immunol*. 2007;27(1):19-35.
30. Thatte UM, Dahanukar SA. Immunotherapeutic modification of *E. coli* peritonitis and bacteremia by *Tinospora cordifolia*. *J Postgrad Med*. 1990;36(1):13-15.
31. Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. *Phytother Res*. 1999;13(4):275-291.
32. Srikanth N, Kumar KS, Kolla S, et al. Evaluation of Panchakarma therapies in cancer: A pilot study. *J Ayurveda Integr Med*. 2021;12(2):237-245.
33. Tillu G, Salvi S, Patwardhan B. Integrative Ayurveda and modern oncology: Hopeful synergism. *J Ayurveda Integr Med*. 2019;10(4):321-323.
34. Raut A, Tillu G, Bhonde R, et al. Perspectives on integrative cancer care: Current evidence and future directions. *Integr Cancer Ther*. 2019;18:1534735419861691.
35. Dhruva A, Miaskowski C, Abrams D, et al. Yoga breathing for cancer chemotherapy-associated symptoms and quality of life: results of a pilot randomized controlled trial. *J Altern Complement Med*. 2012;18(5):473-479.
36. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural products drug discovery. *Curr Sci*. 2004;86(6):789-799.
37. Pandey A, Bani S, Dutt P, et al. Role of traditional medicine in the development of novel drug therapies for cancer. *J Ethnopharmacol*. 2017;210:382-390.
38. Patwardhan B, Tillu G, Vaidya A. AYUSH for cancer care: From claim to evidence. *J Ayurveda Integr Med*. 2021;12(1):1-4.
39. Deng GE, Frenkel M, Cohen L, et al. Evidence-based clinical practice guidelines for integrative oncology: Complementary therapies and botanicals. *CA Cancer J Clin*. 2009;59(3):144-160.
40. Mao JJ, Kapur R. Integrative oncology: An overview. *Am Soc Clin Oncol Educ Book*. 2020;(40):147-156.
41. Narayan R, Rao S, Srikanth N. Role of Ayurveda Rasayana therapy in integrative oncology: A pilot study. *AYU*. 2019;40(3):167-172.
42. Subramaniam A, Kuttan R. Herbal formulation of Triphala suppresses oxidative stress and mucositis in chemotherapy. *Integr Cancer Ther*. 2016;15(2):189-198.
43. Chandran U, Patwardhan B. Network ethnopharmacological evaluation of the Rasayana potential of Ayurvedic herbs in breast cancer care. *J Ethnopharmacol*. 2017;199:243-257.
44. Ramaswamy P, Katiyar C, Ghosh A. Ayurvedic herbs and potential drug interactions in cancer care. *J Integr Med*. 2015;13(6):385-391.
45. Ministry of AYUSH. Standardization of Ayurvedic drugs: Guidelines and protocols. Government of India, 2020.
46. Patwardhan B, Chavan-Gautam P, Gautam M, Tillu G. Ayurveda-based integrative oncology: The road ahead. *J Altern Complement Med*. 2021;27(S1):S67-S75.
47. Venkatasubramanian P, Kotecha R, Mukherjee PK. Ayurveda GCP Guidelines: Need for freedom from the drug-centric model in clinical research. *J Ayurveda Integr Med*. 2020;11(1):1-4.
48. Sagar SM, Wong RK, Zhang Y. Evidence-based complementary and alternative medicine in cancer care. *Curr Oncol*. 2007;14(4):54-60.
49. National Institutes of Health, National Cancer Institute. PDQ: Integrative, Alternative, and Complementary Therapies - Health Professional Version. [Internet]. Updated 2022. Available from: [tps://www.cancer.gov/about-cancer/treatment/cam](https://www.cancer.gov/about-cancer/treatment/cam)

50. Dey S, Sinha D, Gupta P, et al. Systems biology approach in integrative cancer treatment: A paradigm shift. *Integr Cancer Ther.* 2020;19:1534735420923426.
51. Kumar S, Sharma R, Mohapatra S, et al. Pharmacovigilance in Ayurveda: Challenges and solutions. *Anc Sci Life.* 2018;38(1):1-5.
52. Dhawan M, Aggarwal S, Kaur H, et al. Drug-herb interactions: An emerging issue in oncology. *Phytother Res.* 2021;35(7):3582-3599.
53. Ministry of AYUSH. National AYUSH Mission - Guidelines for Integrative Healthcare Models. Government of India, 2023. Available from: <https://www.ayush.gov.in>
54. Frenkel M, Cohen L, Peterson N, et al. Integrative medicine education in oncology: A paradigm shift. *J Cancer Educ.* 2020;35(1):7-14.
55. National Cancer Grid. Integrative Oncology Fellowship Program in India. [Internet]. 2022. Available from: <https://tmc.gov.in/ncg>
56. Mukherjee PK, Venkatesh M, Kumar V. Quality control and standardization of herbal medicines. *Integr Med Res.* 2020;9(3):218-225.
57. Unnikrishnan PM, Misra BB. Reconciliation of Ayurvedic and modern pharmacology: A systems approach. *J Ayurveda Integr Med.* 2018;9(1):1-6.
58. Bodeker G, Kronenberg F. A public health agenda for traditional, complementary, and alternative medicine. *Am J Public Health.* 2002;92(10):1582-1591.
59. WHO. WHO Global Report on Traditional and Complementary Medicine 2019. Geneva: World Health Organization; 2019.
60. Horneber M, Bueschel G, Dennert G, et al. How do experts in complementary and integrative oncology see the future? Results of a Delphi survey. *Support Care Cancer.* 2020;28(3):1353-1361.